Alyn Davies
Associate Director, Medicinal Chemistry AstraZeneca
Alyn Davies, is an Associate Director of Medicinal Chemistry at AstraZeneca, where he leads oncology research programs with a focus on protein degradation and antibody–drug conjugates. He brings deep expertise in PROTACs, molecular glues, and degrader antibody conjugates, complemented by strong leadership experience managing internal and external research teams. Alyn is known for a mentoring driven leadership style that supports scientific growth and innovation. He holds a PhD in chemistry from the University of St Andrews and completed postdoctoral research at the University of Oxford.
Seminars
Tuesday 13th October 2026
PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency
- Highlighting rationale for developing the first reported degrader payloads versus a known oncology target in light of lack of efficacy from small molecule inhibitors
- Laying out medicinal chemistry approaches to optimize PROTAC payload properties and exploring variety of conjugation approaches
- Showcasing potent data generated in preclinical models and highlighting next steps in novel payload development
